Prestige Bought the Factory. The Factory Still Hasn't Cooperated.
A headline beat and a fresh guide-down turn Clear Eyes from a supply-chain problem into a management credibility test.
PBH · Earnings Call · 2026-11-05
Prestige Bought the Factory. The Factory Still Hasn't Cooperated.
Prestige Consumer Healthcare's fiscal second quarter had the shape of a beat and the substance of another warning. Revenue rose 22.7% to $336.3 million, adjusted EPS rose 6% to $1.13, and adjusted EBITDA margin held at 33.6%. But strip out the Breathe Right and LaCorium deals and foreign exchange, and organic revenue fell 1.6%. More important, management cut its fiscal 2027 updated revenue outlook to $1.28 billion-$1.29 billion and adjusted EPS to $4.48-$4.55, with Clear Eyes now expected at less than $20 million for the year. The stock sits roughly 50% below its May 2025 peak and 19% below its August high. The market is no longer debating whether Prestige owns attractive brands. It is debating whether Prestige can reliably make eye drops.
The beat was acquisitions; the miss was execution
Christine Sacco framed the top line plainly: “Q2 revenue of $336.3 million grew 22.7% from $274.1 million in the prior year, and declined 1.6% excluding the effects of foreign currency and the acquisitions” — Christine Sacco, Chief Financial Officer and Chief Operating Officer · 2026-11-05. The deals are real. Breathe Right is now the largest brand in the portfolio, LaCorium brings Dermal Therapy and a leading Australian therapeutic-skincare position, and management still expects about $190 million of combined revenue from the two in fiscal 2027. The base business is not broken either: first-half organic growth was up about 70 basis points, e-commerce consumption is growing mid-teens, and GI brands such as Dramamine and Fleet are benefiting from GLP-1-related nausea and constipation positioning.
But the quarter's quality was softer than the headline. The Q2 beat came partly from acquisition timing and partly from higher-than-expected Clear Eyes sales that were timing, not a change in output. Then came the guide-down. Ron Lombardi was blunt: “we are now forecasting less than $20 million in Clear Eyes sales for the full year” — Ron Lombardi, Chairman, President, and Chief Executive Officer · 2026-11-05. For a brand that once sold nearly 50 million bottles annually at its peak, that is a collapse to roughly 1.5% of company revenue. With zero safety stock, any production hiccup hits sales immediately.
Due to the unique nature of sterile manufacturing, this can at times result in longer-than-expected production downtimes.
That is the crux. Prestige did not merely have a bad supplier quarter. It bought the supplier. Pillar5 was supposed to convert a fragile external supply chain into direct ownership and quality control. The logic is sound, and management says regulatory inspections at Pillar5 have concluded favorably. But ownership also removes the alibi. When output slips now, the problem is inside the four walls Prestige controls.
A pattern, not a one-off
The most damaging part of the call was not the new number. It was the echo. In August, Lombardi said “we expect to see improving levels of output for the second half of the year” — Ron Lombardi, Chairman, President and CEO · 2026-08-06. In May, he described the recurring pattern at Pillar5: “what would start out as an expected 1 week shutdown to do something, turned into 2 weeks, would turn into 3, which would turn into 4” — Ron Lombardi, Chairman, President and CEO · 2026-05-14. And in August, Phil Terpolilli noted that Clear Eyes, because of supply challenges, “represents less than 3% of sales today” — Philip Terpolilli, Unknown (likely IR or Communications) · 2026-08-06. Three months later, the brand is less than $20 million on a $1.28 billion revenue base—smaller still. The recovery has been pushed right again.
The company's own keyword trail tells the story. In late 2025, Clear Eyes supply was the company's top extracted theme. In the current quarter, the fresh high-momentum terms are production variability, safety stock, and consistent output. That is a meaningful shift: the issue has migrated from external availability to internal manufacturing repeatability. Management is trying to reframe the story around control and quality. Investors are likely to hear something simpler: another quarter, another production shortfall.
Lombardi's defense was that “There's no one thing that's impacting production” — Ron Lombardi, Chairman, President, and Chief Executive Officer · 2026-11-05. That may be true, but it is not reassuring. A single identifiable problem can be fixed. A cluster of small issues in sterile manufacturing, with no safety stock, is exactly the kind of problem that takes longer than a quarter to solve. The Q3 Clear Eyes call has already been produced, and the Q4 call assumes output returns to prior levels. That gives the company a narrow runway. If October-type volatility repeats, the fiscal 2028 recovery story loses its anchor.
The other 98.5% is real—and so is the leverage
The bull case is not complicated. Dermal Therapy is a genuine new growth asset: more than 70% of LaCorium sales, a leading lip-care position in Australia, and a therapeutic-skincare brand with a long local heritage. Breathe Right gives Prestige a larger sleep and breathing platform, with an established consumer base and room for adjacent launches. Both acquisitions are integrating quickly, and management says there have been no negative surprises. That is worth something.
But the balance sheet has changed. The deals lifted reported revenue and also pushed Prestige back into a roughly $2.1 billion net-debt position, with leverage around 4x and higher interest expense now a real earnings headwind. Effective net cash was already -$2.0 billion in the last filed quarter. Management is prioritizing debt reduction; the $90 million buyback authorization remains, but Sacco said “at least for the remainder of this fiscal, we're going to be focused on paying down debt” — Christine Sacco, Chief Financial Officer and Chief Operating Officer · 2026-11-05. That is a shift from the prior call, when repurchases were part of the capital-allocation conversation. With the stock halved, the company is choosing the balance sheet over the equity.
Valuation is the tempting part. Price to revenue is roughly 2.0x, and price to free cash flow is around 10x. If Prestige delivers at least $265 million of adjusted free cash flow this year, the math works. But that free cash flow is exactly what Clear Eyes volatility puts at risk. A cheap multiple on a cash flow stream that keeps getting revised is not a value trap yet—but it is not a bargain until production is boring again.
The next proof point
The next catalyst is not a new acquisition or a new brand launch. It is a boring production report. Prestige needs several quarters of repeatable Clear Eyes output, rebuilt safety stock, and a return to full SKU coverage before retailers will give back shelf space and investors will give back the multiple. Until then, the direct ownership decision will read as a double-edged sword: strategically right, operationally unproven.
If Pillar5 stabilizes, the setup is interesting—a defensive portfolio, two newly acquired growth brands, and a stock that has already priced in a lot of disappointment. If it does not, the 'other 98.5%' of the business will keep doing what it is doing, and the tape will keep doing what it has been doing.